Pharvaris N.V. (PHVS)
After hours:
| Previous Close | 19.55 |
| Open | 19.79 |
| Bid | 19.56 x 100 |
| Ask | 21.03 x 100 |
| Day's Range | 19.71 - 21.87 |
| 52 Week Range | 8.20 - 33.00 |
| Volume | |
| Avg. Volume | 74,718 |
| Market Cap | 1.086B |
| Beta (5Y Monthly) | -3.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.69 |
| Earnings Date | Aug 05, 2024 - Aug 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.98 |
GlobeNewswirePharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clini
- GlobeNewswire
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacksExecuting from a strong financial position with cash and cash equivalents of €368 million as of March 31, 2024 ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rec
Simply Wall St.Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
